-1 #(S1 (S (NP (NN SP) (NNS ewes)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJR greater) (NN incorporation)) (PP (IN of) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol))) (PP (IN into) (NP (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +3449) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ total) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +760) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.08))) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NN response) (TO to) (NP (NN _PROT_))) (, ,) (SBAR (IN than) (SINV (VBD did) (NP (NP (NP (NN oCSP) (NNS ewes)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD +553) (CC and) (CD +168)) (NN %)) (PP (IN for) (NP (NP (NN _PROT_)) (CC and) (NP (JJ total) (NN _PROT_))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN endometrium)) (VP (VBN collected) (PP (IN at) (NP (NN ovariectomy/hysterectomy))) (PP (IN on) (NP (NN Day) (CD 16))))))))))))
+1 #(S1 (S (NP (NN SP) (NNS ewes)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJR greater) (NN incorporation)) (PP (IN of) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol))) (PP (IN into) (NP (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +3449) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ total) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +760) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.08))) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NN response) (TO to) (NP (NN _PROT2_))) (, ,) (SBAR (IN than) (SINV (VBD did) (NP (NP (NP (NN oCSP) (NNS ewes)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD +553) (CC and) (CD +168)) (NN %)) (PP (IN for) (NP (NP (NN _PROT_)) (CC and) (NP (JJ total) (NN _PROT_))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN endometrium)) (VP (VBN collected) (PP (IN at) (NP (NN ovariectomy/hysterectomy))) (PP (IN on) (NP (NN Day) (CD 16))))))))))))
-1 #(S1 (S (NP (NN SP) (NNS ewes)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJR greater) (NN incorporation)) (PP (IN of) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol))) (PP (IN into) (NP (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +3449) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ total) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +760) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.08))) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NN response) (TO to) (NP (NN _PROT_))) (, ,) (SBAR (IN than) (SINV (VBD did) (NP (NP (NP (NN oCSP) (NNS ewes)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD +553) (CC and) (CD +168)) (NN %)) (PP (IN for) (NP (NP (NN _PROT2_)) (CC and) (NP (JJ total) (NN _PROT_))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN endometrium)) (VP (VBN collected) (PP (IN at) (NP (NN ovariectomy/hysterectomy))) (PP (IN on) (NP (NN Day) (CD 16))))))))))))
-1 #(S1 (S (NP (NN SP) (NNS ewes)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJR greater) (NN incorporation)) (PP (IN of) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol))) (PP (IN into) (NP (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +3449) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ total) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +760) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.08))) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NN response) (TO to) (NP (NN _PROT_))) (, ,) (SBAR (IN than) (SINV (VBD did) (NP (NP (NP (NN oCSP) (NNS ewes)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD +553) (CC and) (CD +168)) (NN %)) (PP (IN for) (NP (NP (NN _PROT_)) (CC and) (NP (JJ total) (NN _PROT2_))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN endometrium)) (VP (VBN collected) (PP (IN at) (NP (NN ovariectomy/hysterectomy))) (PP (IN on) (NP (NN Day) (CD 16))))))))))))
+1 #(S1 (S (NP (NN SP) (NNS ewes)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJR greater) (NN incorporation)) (PP (IN of) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol))) (PP (IN into) (NP (NP (NP (NP (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +3449) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ total) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +760) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.08))) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NN response) (TO to) (NP (NN _PROT2_))) (, ,) (SBAR (IN than) (SINV (VBD did) (NP (NP (NP (NN oCSP) (NNS ewes)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD +553) (CC and) (CD +168)) (NN %)) (PP (IN for) (NP (NP (NN _PROT_)) (CC and) (NP (JJ total) (NN _PROT_))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN endometrium)) (VP (VBN collected) (PP (IN at) (NP (NN ovariectomy/hysterectomy))) (PP (IN on) (NP (NN Day) (CD 16))))))))))))
-1 #(S1 (S (NP (NN SP) (NNS ewes)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJR greater) (NN incorporation)) (PP (IN of) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol))) (PP (IN into) (NP (NP (NP (NP (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +3449) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ total) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +760) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.08))) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NN response) (TO to) (NP (NN _PROT_))) (, ,) (SBAR (IN than) (SINV (VBD did) (NP (NP (NP (NN oCSP) (NNS ewes)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD +553) (CC and) (CD +168)) (NN %)) (PP (IN for) (NP (NP (NN _PROT2_)) (CC and) (NP (JJ total) (NN _PROT_))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN endometrium)) (VP (VBN collected) (PP (IN at) (NP (NN ovariectomy/hysterectomy))) (PP (IN on) (NP (NN Day) (CD 16))))))))))))
-1 #(S1 (S (NP (NN SP) (NNS ewes)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJR greater) (NN incorporation)) (PP (IN of) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol))) (PP (IN into) (NP (NP (NP (NP (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +3449) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ total) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +760) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.08))) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NN response) (TO to) (NP (NN _PROT_))) (, ,) (SBAR (IN than) (SINV (VBD did) (NP (NP (NP (NN oCSP) (NNS ewes)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD +553) (CC and) (CD +168)) (NN %)) (PP (IN for) (NP (NP (NN _PROT_)) (CC and) (NP (JJ total) (NN _PROT2_))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN endometrium)) (VP (VBN collected) (PP (IN at) (NP (NN ovariectomy/hysterectomy))) (PP (IN on) (NP (NN Day) (CD 16))))))))))))
+1 #(S1 (S (NP (NN SP) (NNS ewes)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJR greater) (NN incorporation)) (PP (IN of) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol))) (PP (IN into) (NP (NP (NP (NP (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +3449) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ total) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +760) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.08))) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NN response) (TO to) (NP (NN _PROT1_))) (, ,) (SBAR (IN than) (SINV (VBD did) (NP (NP (NP (NN oCSP) (NNS ewes)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD +553) (CC and) (CD +168)) (NN %)) (PP (IN for) (NP (NP (NN _PROT2_)) (CC and) (NP (JJ total) (NN _PROT_))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN endometrium)) (VP (VBN collected) (PP (IN at) (NP (NN ovariectomy/hysterectomy))) (PP (IN on) (NP (NN Day) (CD 16))))))))))))
+1 #(S1 (S (NP (NN SP) (NNS ewes)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJR greater) (NN incorporation)) (PP (IN of) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol))) (PP (IN into) (NP (NP (NP (NP (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +3449) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ total) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +760) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.08))) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NN response) (TO to) (NP (NN _PROT1_))) (, ,) (SBAR (IN than) (SINV (VBD did) (NP (NP (NP (NN oCSP) (NNS ewes)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD +553) (CC and) (CD +168)) (NN %)) (PP (IN for) (NP (NP (NN _PROT_)) (CC and) (NP (JJ total) (NN _PROT2_))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN endometrium)) (VP (VBN collected) (PP (IN at) (NP (NN ovariectomy/hysterectomy))) (PP (IN on) (NP (NN Day) (CD 16))))))))))))
-1 #(S1 (S (NP (NN SP) (NNS ewes)) (ADVP (RB also)) (VP (VBD had) (NP (NP (JJR greater) (NN incorporation)) (PP (IN of) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol))) (PP (IN into) (NP (NP (NP (NP (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +3449) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ total) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD +760) (NN %)) (, ,) (NP (NP (NN p)) (QP (JJR less) (IN than) (CD 0.08))) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NN response) (TO to) (NP (NN _PROT_))) (, ,) (SBAR (IN than) (SINV (VBD did) (NP (NP (NP (NN oCSP) (NNS ewes)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD +553) (CC and) (CD +168)) (NN %)) (PP (IN for) (NP (NP (NN _PROT1_)) (CC and) (NP (JJ total) (NN _PROT2_))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN endometrium)) (VP (VBN collected) (PP (IN at) (NP (NN ovariectomy/hysterectomy))) (PP (IN on) (NP (NN Day) (CD 16))))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN oTP-1)) (VP (VP (MD may) (VP (VB prevent) (NP (NN luteolysis)) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (NN development)) (PP (IN of) (NP (NP (JJ endometrial) (NN responsiveness)) (PP (TO to) (NP (NN _PROT1_))))))))))) (CC and) (, ,) (ADVP (RB therefore)) (, ,) (VP (VB reduce) (NP (NP (JJ _PROT2_) (NN synthesis)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN PGF2) (NN alpha))))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN oTP-1)) (VP (VP (MD may) (VP (VB prevent) (NP (NN luteolysis)) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (NN development)) (PP (IN of) (NP (NP (JJ endometrial) (NN responsiveness)) (PP (TO to) (NP (NN _PROT1_))))))))))) (CC and) (, ,) (ADVP (RB therefore)) (, ,) (VP (VB reduce) (NP (NP (JJ _PROT_) (NN synthesis)) (PP (IN of) (NP (NP (NN _PROT2_)) (CC and) (NP (NN PGF2) (NN alpha))))))))))))
+1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN oTP-1)) (VP (VP (MD may) (VP (VB prevent) (NP (NN luteolysis)) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (NN development)) (PP (IN of) (NP (NP (JJ endometrial) (NN responsiveness)) (PP (TO to) (NP (NN _PROT_))))))))))) (CC and) (, ,) (ADVP (RB therefore)) (, ,) (VP (VB reduce) (NP (NP (JJ _PROT1_) (NN synthesis)) (PP (IN of) (NP (NP (NN _PROT2_)) (CC and) (NP (NN PGF2) (NN alpha))))))))))))
-1 #(S1 (S (S (NP (DT The) (NP (NP (NN SGR)) (CC and) (NP (NN RGR)))) (ADVP (RB also)) (VP (VBD had) (NP (JJ different) (JJ endocrine) (NNS profiles)) (PP (PP (IN with)) (, ,) (PP (IN for) (NP (NN example)))) (, ,) (ADVP (RB twice)) (PP (IN as) (NP (NP (JJ high) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.01)) (-RRB- -RRB-)))))) (CC and) (S (NP (NP (NP (NN _PROT2_) (NNS levels)) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.01)) (-RRB- -RRB-))) (PP (IN in) (NP (NN RGR)))) (VP (VBN compared) (PP (TO to) (NP (DT the) (NN SGR)))))))
-1 #(S1 (S (NP (NP (DT This) (NN action)) (PP (IN of) (NP (NN _PROT1_) (CD 25-35)))) (VP (VBZ is) (RB not) (VP (VBN altered) (PP (IN by) (NP (NP (NN pretreatment)) (PP (PP (IN with) (NP (NP (DT the) (NN calcium) (NN channel) (NNS blockers)) (NP (NP (NN nifedipine)) (CC or) (NP (NN cobalt))))) (, ,) (PP (IN with) (NP (NP (NP (DT the) (NN depleter)) (PP (IN of) (NP (JJ intracellular) (NN calcium) (NNS stores)))) (NP (JJ cyclopiazonic) (NN acid)))) (, ,) (CC or) (PP (IN with) (NP (DT the) (NN _PROT2_) (NN _PROT2_) (NN inhibitor) (NN neomycin))))))))))
-1 #(S1 (S (NP (DT These) (NNS findings)) (VP (VBP support) (NP (DT the) (NN concept) (SBAR (IN that) (S (NP (NP (DT the) (JJ mitochondrial) (NN metabolism)) (PP (IN of) (NP (JJ nutrient) (NNS molecules)))) (VP (VBZ is) (NP (NP (DT an) (NN event)) (ADJP (JJ sufficient) (S (VP (VP (TO to) (ADVP (RB acutely)) (VP (VB augment) (NP (NP (NN _PROT1_) (NN release)) (PP (IN from) (NP (DT the) (NN beta) (NN cell)))))) (, ,) (VP (TO to) (VP (VB increase) (NP (NN _PROT2_) (JJ _PROT2_) (NN phosphoinositide) (NN hydrolysis)))) (, ,) (CC and) (VP (TO to) (VP (VB induce) (NP (NP (JJ time-dependent) (NN potentiation)) (PP (IN of) (NP (NN _PROT_) (NN secretion)))))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS findings)) (VP (VBP support) (NP (DT the) (NN concept) (SBAR (IN that) (S (NP (NP (DT the) (JJ mitochondrial) (NN metabolism)) (PP (IN of) (NP (JJ nutrient) (NNS molecules)))) (VP (VBZ is) (NP (NP (DT an) (NN event)) (ADJP (JJ sufficient) (S (VP (VP (TO to) (ADVP (RB acutely)) (VP (VB augment) (NP (NP (NN _PROT1_) (NN release)) (PP (IN from) (NP (DT the) (NN beta) (NN cell)))))) (, ,) (VP (TO to) (VP (VB increase) (NP (NN _PROT_) (JJ _PROT_) (NN phosphoinositide) (NN hydrolysis)))) (, ,) (CC and) (VP (TO to) (VP (VB induce) (NP (NP (JJ time-dependent) (NN potentiation)) (PP (IN of) (NP (NN _PROT2_) (NN secretion)))))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS findings)) (VP (VBP support) (NP (DT the) (NN concept) (SBAR (IN that) (S (NP (NP (DT the) (JJ mitochondrial) (NN metabolism)) (PP (IN of) (NP (JJ nutrient) (NNS molecules)))) (VP (VBZ is) (NP (NP (DT an) (NN event)) (ADJP (JJ sufficient) (S (VP (VP (TO to) (ADVP (RB acutely)) (VP (VB augment) (NP (NP (NN _PROT_) (NN release)) (PP (IN from) (NP (DT the) (NN beta) (NN cell)))))) (, ,) (VP (TO to) (VP (VB increase) (NP (NN _PROT1_) (JJ _PROT1_) (NN phosphoinositide) (NN hydrolysis)))) (, ,) (CC and) (VP (TO to) (VP (VB induce) (NP (NP (JJ time-dependent) (NN potentiation)) (PP (IN of) (NP (NN _PROT2_) (NN secretion)))))))))))))))))
+1 #(S1 (S (NP (NP (NP (NN Signal) (NN transduction)) (PP (IN in) (NP (JJ pancreatic) (NNS beta-cells)))) (: :) (NP (NP (NN Regulation)) (PP (IN of) (NP (NN _PROT1_) (NN secretion))) (PP (IN by) (NP (NP (NN information) (NN flow)) (PP (IN in) (NP (DT the) (NN _PROT2_) (NN _PROT2_) (NN kinase) (NN C) (NN pathway)))))))))
+1 #(S1 (S (NP (NP (DT The) (JJ physiologic) (NN regulation)) (PP (IN of) (NP (JJ glucose-induced) (NN _PROT1_) (NN secretion)))) (VP (VBZ is) (ADJP (JJ dependent) (PP (IN upon) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN information) (NN flow))) (PP (IN in) (NP (NP (NP (DT the) (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN PLC)) (-RRB- -RRB-))) (NN /protein) (NN kinase) (NN C)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (NN signal) (NN transduction) (NN system)))))))))
-1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NN rat) (NN islet)) (VP (VBP are) (VP (VBN cultured) (PP (IN for) (NP (JJ short) (NNS periods))))))) (, ,) (NP (NP (DT the) (NP (NN content)) (CC and) (NP (NN activation))) (PP (IN of) (NP (NN _PROT1_))) (PP (IN in) (NP (NP (NP (NN response)) (PP (TO to) (NP (NN glucose) (NNS decreases)))) (CC and) (NP (NP (DT this) (JJ biochemical) (NN defect)) (PP (IN in) (NP (NN signal) (NN transduction))))))) (VP (VBZ is) (VP (VBN paralleled) (PP (IN by) (NP (NP (JJ significant) (NNS reductions)) (PP (IN in) (NP (JJ glucose-induced) (NN _PROT2_) (NN secretion)))))))))
+1 #(S1 (S (S (NP (JJ Biphasic) (NN _PROT1_) (NN secretion)) (VP (MD can) (VP (VB be) (VP (VBN evoked))))) (CC and) (S (NP (JJ time-dependent) (NN potentiation)) (VP (MD can) (VP (VB be) (VP (VBN induced) (PP (IN in) (NP (NN mouse) (NNS islets))) (PP (IN by) (NP (NP (NN carbachol)) (, ,) (NP (NP (DT an) (NN agonist)) (SBAR (WHNP (WDT that)) (S (VP (VBZ activates) (NP (NP (DT an) (NN isozyme)) (PP (IN of) (NP (NN _PROT2_))) (ADJP (JJ distinct) (PP (IN from) (NP (NP (DT that)) (VP (VBN activated) (PP (IN by) (NP (NN glucose))))))))))))))))))))
+1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN taken) (PP (IN in) (NP (PRP$ their) (NN entirety)))))) (, ,) (S (NP (DT the) (JJ experimental) (NN evidence)) (VP (VBZ suggests) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBZ is) (NP (NP (DT an) (JJ essential) (NN component)) (PP (IN in) (NP (NP (DT the) (JJ physiologic) (NN regulation)) (PP (IN of) (NP (NN _PROT2_) (NN secretion))))))))) (CC and) (SBAR (IN that) (S (NP (NP (VBN disordered) (NN activation)) (PP (IN of) (NP (DT the) (NN enzyme)))) (VP (VBZ culminates) (PP (IN in) (NP (VBN disordered) (NN _PROT_) (NN release)))))))))))
-1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN taken) (PP (IN in) (NP (PRP$ their) (NN entirety)))))) (, ,) (S (NP (DT the) (JJ experimental) (NN evidence)) (VP (VBZ suggests) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBZ is) (NP (NP (DT an) (JJ essential) (NN component)) (PP (IN in) (NP (NP (DT the) (JJ physiologic) (NN regulation)) (PP (IN of) (NP (NN _PROT_) (NN secretion))))))))) (CC and) (SBAR (IN that) (S (NP (NP (VBN disordered) (NN activation)) (PP (IN of) (NP (DT the) (NN enzyme)))) (VP (VBZ culminates) (PP (IN in) (NP (VBN disordered) (NN _PROT2_) (NN release)))))))))))
-1 #(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN taken) (PP (IN in) (NP (PRP$ their) (NN entirety)))))) (, ,) (S (NP (DT the) (JJ experimental) (NN evidence)) (VP (VBZ suggests) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBZ is) (NP (NP (DT an) (JJ essential) (NN component)) (PP (IN in) (NP (NP (DT the) (JJ physiologic) (NN regulation)) (PP (IN of) (NP (NN _PROT1_) (NN secretion))))))))) (CC and) (SBAR (IN that) (S (NP (NP (VBN disordered) (NN activation)) (PP (IN of) (NP (DT the) (NN enzyme)))) (VP (VBZ culminates) (PP (IN in) (NP (VBN disordered) (NN _PROT2_) (NN release)))))))))))
-1 #(S1 (S (NP (NP (JJ Cellular) (NN preincubation)) (PP (IN with) (NP (NP (NP (ADJP (CD 200) (NN microg/ml)) (NNS antibodies)) (PP (IN against) (NP (NP (DT the) (NN inositolphosphoglycan) (-LRB- -LRB-) (NN IPG) (-RRB- -RRB-) (NN moiety)) (PP (IN of) (NP (DT the) (NN GPI-anchor))))) (PRN (-LRB- -LRB-) (NP (NP (NN Ab)) (PRN (-LRB- -LRB-) (NP (NN IPG)) (-RRB- -RRB-))) (-RRB- -RRB-)) (, ,)) (CC or) (NP (NP (NN depletion)) (PP (IN in) (NP (JJ GPI-anchored) (NNS proteins))) (PP (IN by) (NP (NP (JJ cellular) (NN pretreatment)) (PP (IN with) (NP (NP (ADJP (CD 0.5) (NN U/ml)) (NN _PROT1_)) (, ,) (NP (NP (CD 1) (NN mM) (NN _PROT2_)) (CC and) (NP (CD 2) (NN HU/ml) (JJ streptolysin-O))) (, ,) (CC or) (NP (NP (NN depletion)) (PP (IN in) (NP (NN membrane) (NN cholesterol) (NN content))) (PP (IN by) (NP (NP (NP (NN filipin)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN microg/ml)) (-RRB- -RRB-))) (, ,) (NP (NP (NN digitonin)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN microg/ml)) (-RRB- -RRB-))) (CC and) (NP (NP (NN cholesterol) (NN oxidase)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN U/ml)) (-RRB- -RRB-)))))))))))))) (VP (VBZ decreases) (NP (DT the) (NN HDL3-signal)) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NP (DT a) (JJ lipolytic) (NN cleavage)) (PP (IN of) (NP (JJ GPI-anchored) (NNS proteins)))))))))))
+1 #(S1 (S (NP (NP (NP (NP (JJ _PROT1_) (NN beta) (NN protein)) (PRN (-LRB- -LRB-) (NP (CD 25-35)) (-RRB- -RRB-))) (NN stimulation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_))) (PP (IN in) (NP (NN LA-N-2) (NNS cells))))))
+1 #(S1 (S (NP (NP (DT This) (NN _PROT1_) (NN _PROT1_) (NN stimulation)) (PP (IN by) (NP (JJ _PROT2_) (NN beta) (NN protein)))) (VP (VBD appeared) (S (VP (TO to) (VP (VB be) (NP (NN pertussis) (NN toxin) (JJ sensitive))))))))
+1 #(S1 (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (NP (DT this) (NN _PROT1_) (NN _PROT1_) (NN stimulation)) (PP (IN by) (NP (JJ _PROT2_) (NN beta) (NN protein)))) (VP (VBZ is) (NP (DT a) (JJ receptor-mediated) (NN process))))))))
+1 #(S1 (S (NP (NP (NN _PROT1_) (NN beta) (NN protein) (NN stimulation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_)))) (VP (VBD was) (ADJP (JJ absent) (PP (IN from) (NP (NP (NN LA-N-2) (NNS cells)) (VP (ADVP (RB previously)) (VBN treated) (PP (IN with) (NP (NP (NN norepinephrine)) (, ,) (NP (NP (JJ trans-1-amino-1,3-cyclopentanedicarboxylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN t-ACPD)) (-RRB- -RRB-))) (, ,) (NP (NN bombesin)) (, ,) (CC or) (NP (NN _PROT_) (NN beta) (NN peptide)))))))))))
-1 #(S1 (S (NP (NP (NN _PROT1_) (NN beta) (NN protein) (NN stimulation)) (PP (IN of) (NP (NN _PROT_) (NN _PROT_)))) (VP (VBD was) (ADJP (JJ absent) (PP (IN from) (NP (NP (NN LA-N-2) (NNS cells)) (VP (ADVP (RB previously)) (VBN treated) (PP (IN with) (NP (NP (NN norepinephrine)) (, ,) (NP (NP (JJ trans-1-amino-1,3-cyclopentanedicarboxylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN t-ACPD)) (-RRB- -RRB-))) (, ,) (NP (NN bombesin)) (, ,) (CC or) (NP (NN _PROT2_) (NN beta) (NN peptide)))))))))))
-1 #(S1 (S (NP (NP (NN _PROT_) (NN beta) (NN protein) (NN stimulation)) (PP (IN of) (NP (NN _PROT1_) (NN _PROT1_)))) (VP (VBD was) (ADJP (JJ absent) (PP (IN from) (NP (NP (NN LA-N-2) (NNS cells)) (VP (ADVP (RB previously)) (VBN treated) (PP (IN with) (NP (NP (NN norepinephrine)) (, ,) (NP (NP (JJ trans-1-amino-1,3-cyclopentanedicarboxylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN t-ACPD)) (-RRB- -RRB-))) (, ,) (NP (NN bombesin)) (, ,) (CC or) (NP (NN _PROT2_) (NN beta) (NN peptide)))))))))))
+1 #(S1 (S (NP (PRP It)) (VP (VBZ is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (DT this) (VBN observed) (NN _PROT1_) (NN beta) (NN protein) (NN stimulation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_)))) (VP (MD may) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ elevated) (NN quantity)) (PP (IN of) (NP (NN inositol))) (VP (VBN seen) (PP (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (NP (NN Alzheimer) (POS 's) (NN disease)) (NNS patients)))))))))))))))))
+1 #(S1 (S (NP (NN _PROT1_)) (VP (VBZ stimulates) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (DT the) (NN glycosyl) (JJ phosphatidylinositol-anchored) (NN membrane) (NN dipeptidase))) (PP (IN from) (NP (NN 3T3-L1) (NNS adipocytes)))) (PP (IN through) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (DT a) (NN _PROT2_) (NN _PROT2_))))))))
+1 #(S1 (S (NP (NP (DT The) (JJ hydrophilic) (NN form)) (PP (IN of) (NP (NP (NN MDP)) (VP (VBN released) (PP (IN from) (NP (NP (DT the) (NNS cells)) (PP (IN on) (NP (NP (NN stimulation)) (PP (IN with) (NP (NN _PROT1_))))))))))) (VP (VBD was) (VP (VBN recognized) (PP (IN by) (NP (NP (NNS antibodies)) (PP (IN against) (NP (NP (DT the) (NN inositol) (JJ 1,2-cyclic) (NN monophosphate)) (VP (VBG cross-reacting) (NP (NN determinant))))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (PRP it)) (VP (VBD had) (VP (VBN been) (VP (VBN generated) (PP (IN by) (NP (NP (NN cleavage)) (PP (IN of) (NP (PRP$ its) (NN GPI) (NN anchor))))) (PP (IN through) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (DT a) (NN _PROT2_) (NN _PROT2_))))))))))))))))
-1 #(S1 (S (SBAR (IN After) (S (NP (NP (NN _PROT1_) (NN _PROT1_) (NN _PROT1_)) (NN activity)) (VP (VBD was) (ADVP (RB functionally)) (VP (VBN depleted) (PP (IN by) (S (VP (VBG treating) (NP (NNS cells)) (PP (IN with) (NP (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate)) (PP (IN for) (NP (CD 24) (NNS hours)))))))))))) (, ,) (NP (PRP _PROT2_)) (VP (VBD did) (RB not) (VP (VB augment) (NP (JJ IL-1beta-induced) (NN NO) (NN production))))))
+1 #(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN inhibited) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT the) (NN _PROT2_) (NN _PROT2_) (NN _PROT2_) (NN inhibitor) (NN calphostin) (NN C)))))))))
+1 #(S1 (S (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NNS _PROT1_)))) (VP (VBD increased) (NP (NP (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)) (NN activity)) (PP (IN in) (NP (JJ cardiac) (NNS myocytes)))))) (, ,) (CC and) (S (NP (PRP$ its) (NN effect)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN inhibited) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN calphostin) (NN C))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP support) (NP (DT the) (NN hypothesis) (SBAR (SBAR (IN that) (S (NP (DT the) (NN heart)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN target) (NN organ)) (PP (IN for) (NP (NN _PROT1_)))))))) (CC and) (SBAR (IN that) (S (NP (NN _PROT2_)) (VP (VBZ modulates) (NP (NP (JJ IL-1beta-induced) (NN iNOS) (NN expression)) (PP (IN in) (NP (NNS myocytes)))) (PP (IN through) (NP (NP (DT the) (NN V1a) (NN receptor)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN mediated) (ADVP (ADVP (IN at) (JJS least)) (RB partially)) (PP (IN via) (NP (NP (NN activation)) (PP (IN of) (NP (NN _PROT_) (NN _PROT_) (NN _PROT_)))))))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP support) (NP (DT the) (NN hypothesis) (SBAR (SBAR (IN that) (S (NP (DT the) (NN heart)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN target) (NN organ)) (PP (IN for) (NP (NN _PROT1_)))))))) (CC and) (SBAR (IN that) (S (NP (NN _PROT_)) (VP (VBZ modulates) (NP (NP (JJ IL-1beta-induced) (NN iNOS) (NN expression)) (PP (IN in) (NP (NNS myocytes)))) (PP (IN through) (NP (NP (DT the) (NN V1a) (NN receptor)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN mediated) (ADVP (ADVP (IN at) (JJS least)) (RB partially)) (PP (IN via) (NP (NP (NN activation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)))))))))))))))))))
+1 #(S1 (S (NP (DT These) (NNS results)) (VP (VBP support) (NP (DT the) (NN hypothesis) (SBAR (SBAR (IN that) (S (NP (DT the) (NN heart)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN target) (NN organ)) (PP (IN for) (NP (NN _PROT_)))))))) (CC and) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VBZ modulates) (NP (NP (JJ IL-1beta-induced) (NN iNOS) (NN expression)) (PP (IN in) (NP (NNS myocytes)))) (PP (IN through) (NP (NP (DT the) (NN V1a) (NN receptor)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN mediated) (ADVP (ADVP (IN at) (JJS least)) (RB partially)) (PP (IN via) (NP (NP (NN activation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)))))))))))))))))))
+1 #(S1 (S (NP (PRP We)) (VP (VBP have) (ADVP (RB recently)) (VP (VBN shown) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VBZ causes) (NP (NP (DT a) (ADJP (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)) (-LRB- -LRB-) (NN PKC) (-RRB- -RRB-) (JJ -dependent)) (NN increase)) (PP (IN in) (NP (NP (NN ACTH) (NN release)) (CC and) (NP (NN biosynthesis)))) (PP (IN in) (NP (NP (NN ovine) (JJ anterior) (NN pituitary)) (NNS cells)))))))))))
+1 #(S1 (S (PP (IN In) (NP (DT these) (NNS cells))) (, ,) (S (S (NP (NN _PROT1_)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (DT the) (NN translocation)) (PP (IN of) (NP (NN _PROT2_))) (PP (IN from) (NP (DT the) (NN cytosol))) (PP (TO to) (NP (NP (DT the) (NN cell) (NN membrane)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ maximal) (PP (IN at) (NP (CD 5) (NN min)))))))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ intracellular) (NNS events)) (ADJP (JJ distal) (PP (TO to) (NP (NP (NP (NN _PROT_) (NN _PROT_) (NN _PROT_)) (NN activation)) (SBAR (WHNP (WDT that)) (S (VP (VBP underlie) (NP (NN ACTH) (NN secretion))))))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB well)) (VP (VBN characterized) (PP (TO to) (NP (NN date))))))))))
-1 #(S1 (S (PP (IN In) (NP (DT these) (NNS cells))) (, ,) (S (S (NP (NN _PROT1_)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (DT the) (NN translocation)) (PP (IN of) (NP (NN _PROT_))) (PP (IN from) (NP (DT the) (NN cytosol))) (PP (TO to) (NP (NP (DT the) (NN cell) (NN membrane)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ maximal) (PP (IN at) (NP (CD 5) (NN min)))))))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ intracellular) (NNS events)) (ADJP (JJ distal) (PP (TO to) (NP (NP (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)) (NN activation)) (SBAR (WHNP (WDT that)) (S (VP (VBP underlie) (NP (NN ACTH) (NN secretion))))))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB well)) (VP (VBN characterized) (PP (TO to) (NP (NN date))))))))))
-1 #(S1 (S (PP (IN In) (NP (DT these) (NNS cells))) (, ,) (S (S (NP (NN _PROT_)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (DT the) (NN translocation)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN from) (NP (DT the) (NN cytosol))) (PP (TO to) (NP (NP (DT the) (NN cell) (NN membrane)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ maximal) (PP (IN at) (NP (CD 5) (NN min)))))))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ intracellular) (NNS events)) (ADJP (JJ distal) (PP (TO to) (NP (NP (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)) (NN activation)) (SBAR (WHNP (WDT that)) (S (VP (VBP underlie) (NP (NN ACTH) (NN secretion))))))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB well)) (VP (VBN characterized) (PP (TO to) (NP (NN date))))))))))
-1 #(S1 (S (SBAR (IN Since) (S (NP (DT the) (NN MARCKS) (NN protein)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NN neurosecretion)))))) (CC and) (VP (VBZ is) (VP (VBN phosphorylated) (PP (IN by) (NP (NN _PROT1_))) (PP (IN in) (NP (NNS synaptosomes)))))))) (, ,) (S (S (NP (NNS studies)) (VP (VBD were) (VP (VBN carried) (PRT (RP out)) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NN _PROT2_)) (VP (MD might) (VP (VB cause) (NP (NN MARCKS) (NN phosphorylation)) (PP (IN in) (NP (DT the) (NN ovine) (JJ anterior) (NN pituitary))))))))))))) (, ,) (CC and) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (DT this) (NN phenomenon)) (VP (MD might) (VP (VB be) (VP (ADVP (RB temporally)) (VBN correlated) (PP (IN with) (NP (NP (NN _PROT_) (NN translocation)) (CC and) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NN ACTH)))))))))))))))))
-1 #(S1 (S (SBAR (IN Since) (S (NP (DT the) (NN MARCKS) (NN protein)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NN neurosecretion)))))) (CC and) (VP (VBZ is) (VP (VBN phosphorylated) (PP (IN by) (NP (NN _PROT1_))) (PP (IN in) (NP (NNS synaptosomes)))))))) (, ,) (S (S (NP (NNS studies)) (VP (VBD were) (VP (VBN carried) (PRT (RP out)) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NN _PROT_)) (VP (MD might) (VP (VB cause) (NP (NN MARCKS) (NN phosphorylation)) (PP (IN in) (NP (DT the) (NN ovine) (JJ anterior) (NN pituitary))))))))))))) (, ,) (CC and) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (DT this) (NN phenomenon)) (VP (MD might) (VP (VB be) (VP (ADVP (RB temporally)) (VBN correlated) (PP (IN with) (NP (NP (NN _PROT2_) (NN translocation)) (CC and) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NN ACTH)))))))))))))))))
-1 #(S1 (S (SBAR (IN Since) (S (NP (DT the) (NN MARCKS) (NN protein)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NN neurosecretion)))))) (CC and) (VP (VBZ is) (VP (VBN phosphorylated) (PP (IN by) (NP (NN _PROT_))) (PP (IN in) (NP (NNS synaptosomes)))))))) (, ,) (S (S (NP (NNS studies)) (VP (VBD were) (VP (VBN carried) (PRT (RP out)) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NN _PROT1_)) (VP (MD might) (VP (VB cause) (NP (NN MARCKS) (NN phosphorylation)) (PP (IN in) (NP (DT the) (NN ovine) (JJ anterior) (NN pituitary))))))))))))) (, ,) (CC and) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (DT this) (NN phenomenon)) (VP (MD might) (VP (VB be) (VP (ADVP (RB temporally)) (VBN correlated) (PP (IN with) (NP (NP (NN _PROT2_) (NN translocation)) (CC and) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NN ACTH)))))))))))))))))
-1 #(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (: :) (S (S (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NN _PROT1_)) (VP (VBZ causes) (NP (NP (DT a) (ADJP (ADJP (JJ rapid)) (, ,) (CC and) (ADJP (JJ reversible)) (, ,)) (NN phosphorylation)) (PP (IN of) (NP (DT the) (NN MARCKS) (NN protein)))) (PP (IN in) (NP (DT the) (NN ovine) (JJ anterior) (NN pituitary))))) (: ;) (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (IN since) (S (NP (NP (DT the) (JJ _PROT2_) (NN increase)) (PP (IN in) (NP (NN MARCKS) (NN phosphorylation)))) (VP (VBZ occurs) (ADJP (RB much) (JJR earlier) (PP (IN in) (NP (NP (DT these) (NNS cells)) (SBAR (IN than) (S (VP (VBZ does) (ADJP (NN _PROT_) (JJ trans-location)))))))))))) (, ,) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB provide) (NP (DT a) (ADJP (RBR more) (JJ sensitive)) (NN index)) (PP (IN of) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN _PROT_) (NN activation))) (PP (IN than) (NP (DT the) (NN translocation) (NN assay)))))))))) (: ;) (S (NP (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (DT the) (JJ close) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (NN MARCKS) (NN phosphorylation)) (CC and) (NP (NP (DT the) (JJ rapid) (JJ early) (NN release)) (PP (IN of) (NP (NN ACTH))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ initial) (JJ intracellular) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP underly) (NP (NP (NN exocytosis)) (PP (IN of) (NP (DT the) (NN hormone)))))))))))))))) (. .)))
-1 #(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (: :) (S (S (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NN _PROT1_)) (VP (VBZ causes) (NP (NP (DT a) (ADJP (ADJP (JJ rapid)) (, ,) (CC and) (ADJP (JJ reversible)) (, ,)) (NN phosphorylation)) (PP (IN of) (NP (DT the) (NN MARCKS) (NN protein)))) (PP (IN in) (NP (DT the) (NN ovine) (JJ anterior) (NN pituitary))))) (: ;) (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (IN since) (S (NP (NP (DT the) (JJ _PROT_) (NN increase)) (PP (IN in) (NP (NN MARCKS) (NN phosphorylation)))) (VP (VBZ occurs) (ADJP (RB much) (JJR earlier) (PP (IN in) (NP (NP (DT these) (NNS cells)) (SBAR (IN than) (S (VP (VBZ does) (ADJP (NN _PROT2_) (JJ trans-location)))))))))))) (, ,) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB provide) (NP (DT a) (ADJP (RBR more) (JJ sensitive)) (NN index)) (PP (IN of) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN _PROT_) (NN activation))) (PP (IN than) (NP (DT the) (NN translocation) (NN assay)))))))))) (: ;) (S (NP (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (DT the) (JJ close) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (NN MARCKS) (NN phosphorylation)) (CC and) (NP (NP (DT the) (JJ rapid) (JJ early) (NN release)) (PP (IN of) (NP (NN ACTH))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ initial) (JJ intracellular) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP underly) (NP (NP (NN exocytosis)) (PP (IN of) (NP (DT the) (NN hormone)))))))))))))))) (. .)))
-1 #(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (: :) (S (S (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NN _PROT1_)) (VP (VBZ causes) (NP (NP (DT a) (ADJP (ADJP (JJ rapid)) (, ,) (CC and) (ADJP (JJ reversible)) (, ,)) (NN phosphorylation)) (PP (IN of) (NP (DT the) (NN MARCKS) (NN protein)))) (PP (IN in) (NP (DT the) (NN ovine) (JJ anterior) (NN pituitary))))) (: ;) (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (IN since) (S (NP (NP (DT the) (JJ _PROT_) (NN increase)) (PP (IN in) (NP (NN MARCKS) (NN phosphorylation)))) (VP (VBZ occurs) (ADJP (RB much) (JJR earlier) (PP (IN in) (NP (NP (DT these) (NNS cells)) (SBAR (IN than) (S (VP (VBZ does) (ADJP (NN _PROT_) (JJ trans-location)))))))))))) (, ,) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB provide) (NP (DT a) (ADJP (RBR more) (JJ sensitive)) (NN index)) (PP (IN of) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN _PROT2_) (NN activation))) (PP (IN than) (NP (DT the) (NN translocation) (NN assay)))))))))) (: ;) (S (NP (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (DT the) (JJ close) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (NN MARCKS) (NN phosphorylation)) (CC and) (NP (NP (DT the) (JJ rapid) (JJ early) (NN release)) (PP (IN of) (NP (NN ACTH))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ initial) (JJ intracellular) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP underly) (NP (NP (NN exocytosis)) (PP (IN of) (NP (DT the) (NN hormone)))))))))))))))) (. .)))
-1 #(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (: :) (S (S (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NN _PROT_)) (VP (VBZ causes) (NP (NP (DT a) (ADJP (ADJP (JJ rapid)) (, ,) (CC and) (ADJP (JJ reversible)) (, ,)) (NN phosphorylation)) (PP (IN of) (NP (DT the) (NN MARCKS) (NN protein)))) (PP (IN in) (NP (DT the) (NN ovine) (JJ anterior) (NN pituitary))))) (: ;) (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (IN since) (S (NP (NP (DT the) (JJ _PROT1_) (NN increase)) (PP (IN in) (NP (NN MARCKS) (NN phosphorylation)))) (VP (VBZ occurs) (ADJP (RB much) (JJR earlier) (PP (IN in) (NP (NP (DT these) (NNS cells)) (SBAR (IN than) (S (VP (VBZ does) (ADJP (NN _PROT2_) (JJ trans-location)))))))))))) (, ,) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB provide) (NP (DT a) (ADJP (RBR more) (JJ sensitive)) (NN index)) (PP (IN of) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN _PROT_) (NN activation))) (PP (IN than) (NP (DT the) (NN translocation) (NN assay)))))))))) (: ;) (S (NP (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (DT the) (JJ close) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (NN MARCKS) (NN phosphorylation)) (CC and) (NP (NP (DT the) (JJ rapid) (JJ early) (NN release)) (PP (IN of) (NP (NN ACTH))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ initial) (JJ intracellular) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP underly) (NP (NP (NN exocytosis)) (PP (IN of) (NP (DT the) (NN hormone)))))))))))))))) (. .)))
-1 #(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (: :) (S (S (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NN _PROT_)) (VP (VBZ causes) (NP (NP (DT a) (ADJP (ADJP (JJ rapid)) (, ,) (CC and) (ADJP (JJ reversible)) (, ,)) (NN phosphorylation)) (PP (IN of) (NP (DT the) (NN MARCKS) (NN protein)))) (PP (IN in) (NP (DT the) (NN ovine) (JJ anterior) (NN pituitary))))) (: ;) (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (IN since) (S (NP (NP (DT the) (JJ _PROT1_) (NN increase)) (PP (IN in) (NP (NN MARCKS) (NN phosphorylation)))) (VP (VBZ occurs) (ADJP (RB much) (JJR earlier) (PP (IN in) (NP (NP (DT these) (NNS cells)) (SBAR (IN than) (S (VP (VBZ does) (ADJP (NN _PROT_) (JJ trans-location)))))))))))) (, ,) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB provide) (NP (DT a) (ADJP (RBR more) (JJ sensitive)) (NN index)) (PP (IN of) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN _PROT2_) (NN activation))) (PP (IN than) (NP (DT the) (NN translocation) (NN assay)))))))))) (: ;) (S (NP (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (DT the) (JJ close) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (NN MARCKS) (NN phosphorylation)) (CC and) (NP (NP (DT the) (JJ rapid) (JJ early) (NN release)) (PP (IN of) (NP (NN ACTH))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ initial) (JJ intracellular) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP underly) (NP (NP (NN exocytosis)) (PP (IN of) (NP (DT the) (NN hormone)))))))))))))))) (. .)))
-1 #(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (: :) (S (S (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NN _PROT_)) (VP (VBZ causes) (NP (NP (DT a) (ADJP (ADJP (JJ rapid)) (, ,) (CC and) (ADJP (JJ reversible)) (, ,)) (NN phosphorylation)) (PP (IN of) (NP (DT the) (NN MARCKS) (NN protein)))) (PP (IN in) (NP (DT the) (NN ovine) (JJ anterior) (NN pituitary))))) (: ;) (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (IN since) (S (NP (NP (DT the) (JJ _PROT_) (NN increase)) (PP (IN in) (NP (NN MARCKS) (NN phosphorylation)))) (VP (VBZ occurs) (ADJP (RB much) (JJR earlier) (PP (IN in) (NP (NP (DT these) (NNS cells)) (SBAR (IN than) (S (VP (VBZ does) (ADJP (NN _PROT1_) (JJ trans-location)))))))))))) (, ,) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB provide) (NP (DT a) (ADJP (RBR more) (JJ sensitive)) (NN index)) (PP (IN of) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN _PROT2_) (NN activation))) (PP (IN than) (NP (DT the) (NN translocation) (NN assay)))))))))) (: ;) (S (NP (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (DT the) (JJ close) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (NN MARCKS) (NN phosphorylation)) (CC and) (NP (NP (DT the) (JJ rapid) (JJ early) (NN release)) (PP (IN of) (NP (NN ACTH))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN MARCKS) (NN phosphorylation)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ initial) (JJ intracellular) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP underly) (NP (NP (NN exocytosis)) (PP (IN of) (NP (DT the) (NN hormone)))))))))))))))) (. .)))
+1 #(S1 (S (NP (DT These) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN bradykinin)) (, ,) (PP (IN like) (NP (NN _PROT1_))) (, ,) (VP (VBZ activates) (NP (NP (NN phospholipase) (NN C)) (SBAR (WHNP (WDT which)) (S (VP (VBZ generates) (NP (NN _PROT2_)) (PP (IN with) (NP (NP (DT a) (JJ subsequent) (NN release)) (PP (IN of) (NP (NN Ca2+))) (PP (IN from) (NP (NP (JJ intracellular) (NNS stores)) (VP (VBN followed) (PP (IN by) (NP (JJ store-operated) (NN Ca2+) (NN influx))))))))))))))))))
+1 #(S1 (S (S (NP (NP (NP (NN _PROT1_) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (NNS inhibitors)) (VP (VBD reversed) (NP (NN _PROT2_) (NN inhibition)))) (, ,) (IN whereas) (S (NP (NN _PROT_) (NN activator)) (VP (VBD inhibited) (NP (NN nitrite) (NN production))))))
-1 #(S1 (S (S (NP (NP (NP (NN _PROT1_) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (NNS inhibitors)) (VP (VBD reversed) (NP (NN _PROT_) (NN inhibition)))) (, ,) (IN whereas) (S (NP (NN _PROT2_) (NN activator)) (VP (VBD inhibited) (NP (NN nitrite) (NN production))))))
-1 #(S1 (S (S (NP (NP (NP (NN _PROT_) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (NNS inhibitors)) (VP (VBD reversed) (NP (NN _PROT1_) (NN inhibition)))) (, ,) (IN whereas) (S (NP (NN _PROT2_) (NN activator)) (VP (VBD inhibited) (NP (NN nitrite) (NN production))))))
+1 #(S1 (S (NP (NP (DT The) (JJ inhibitory) (NN action)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBZ involves) (NP (CC both) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN _PROT2_)))) (CC and) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (NN iNOS) (NN mRNA))))) (PP (IN in) (NP (VBN cultured) (NN rat) (NN GMC))))))
-1 #(S1 (S (NP (NP (NP (DT An) (NN inhibitor)) (PP (IN of) (NP (NN _PROT1_)))) (, ,) (NP (NP (NN Ro31-8220)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN microM)) (-RRB- -RRB-))) (, ,)) (VP (VBD abolished) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN PDBu))) (S (VP (TO to) (VP (VB decrease) (NP (NP (NP (NN [Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-) (-RRB- -RSB-))) (PRN (-LRB- -LRB-) (NP (NN i)) (-RRB- -RRB-))))))) (, ,) (PP (IN without) (S (VP (VBG affecting) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NP (ADJP (ADJP (JJ maximal)) (CC or) (ADJP (JJ submaximal))) (NNS concentrations)) (PP (IN of) (NP (NN _PROT2_))))))))))))
-1 #(S1 (S (NP (NP (DT The) (NN etiology)) (PP (IN for) (NP (NP (NN diabetes) (NN mellitus)) (PP (IN in) (NP (NNS PWS)))))) (VP (MD may) (VP (VB be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (JJ morbid) (NN obesity)) (CC and) (NP (JJ consequent) (NN _PROT1_) (NN resistance))))) (, ,) (SBAR (IN because) (S (NP (NP (NP (DT a) (NN decrease)) (PP (IN of) (NP (JJ _PROT2_) (NNS neurons)))) (CC and) (NP (NP (NN leptin) (NN resistance)) (PP (IN in) (NP (NNS PWS))))) (VP (MD may) (VP (VB cause) (NP (NN hyperphagia)) (, ,) (S (VP (VBG inducing) (NP (NN obesity))))))))))))
+1 #(S1 (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN AVP)) (-RRB- -RRB-))) (VP (VBZ stimulates) (NP (NP (NP (NN heat) (NN shock) (NN protein) (CD 27)) (PRN (-LRB- -LRB-) (NP (NN HSP27)) (-RRB- -RRB-))) (NN induction)) (PP (IN through) (NP (NP (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)) (NN activation)) (PP (IN in) (NP (JJ aortic) (JJ smooth) (NN muscle) (NN A10) (NNS cells)))))))))))
+1 #(S1 (S (NP (NP (NP (NN Calphostin) (NN C)) (CC and) (NP (NN ET-18-OCH) (-LRB- -LRB-) (CD 3) (-RRB- -RRB-))) (, ,) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NN _PROT1_) (NN _PROT1_) (NN _PROT1_)))) (, ,)) (VP (VBD reduced) (NP (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (NN p38) (NN MAP) (NN kinase))) (PP (IN by) (NP (NN _PROT2_)))))))
+1 #(S1 (S (NP (NP (NP (NN Ca2+) (NN signalling)) (PP (IN in) (NP (NN rat) (JJ vascular) (NN smooth) (NN muscle) (NNS cells)))) (: :) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN _PROT1_) (NN _PROT1_) (NN _PROT1_))) (PP (IN at) (NP (NP (JJ physiological) (NN vasoconstrictor) (NNS concentrations)) (PP (IN of) (NP (NN _PROT2_)))))))))
-1 #(S1 (S (S (NP (NP (DT The) (NP (NP (NN _PROT1_) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (NN activator) (NN 4beta-phorbol) (NN 12-myristate) (NN 13-acetate)) (PRN (-LRB- -LRB-) (NP (NP (NN PMA)) (, ,) (NP (CD 100) (NN pM) (TO to) (CD 200) (NN nM))) (-RRB- -RRB-)) (, ,)) (ADVP (RB also)) (VP (VBD stimulated) (NP (NN Ca2+) (NN spiking)))) (CC and) (S (NP (DT this) (NN effect)) (VP (VBD was) (ADJP (JJ additive)) (PP (IN with) (NP (NP (DT a) (JJ submaximal) (NN concentration)) (PP (IN of) (NP (NN _PROT2_))))) (PRN (-LRB- -LRB-) (NP (CD 50) (NN pM)) (-RRB- -RRB-))))))
+1 #(S1 (S (NP (NP (DT The) (NN _PROT1_) (NNS _PROT1_)) (NP (NP (NP (NN Ro-31-8220)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN microM)) (-RRB- -RRB-))) (CC and) (NP (NP (NN calphostin) (NN C)) (PRN (-LRB- -LRB-) (NP (CD 250) (NN nM)) (-RRB- -RRB-))))) (ADVP (RB completely)) (VP (VBD blocked) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NN Ca2+) (NN spiking))) (PP (IN by) (NP (CC either) (NP (NN PMA)) (CC or) (NP (NN _PROT2_))))))))
+1 #(S1 (S (NP (NP (JJ Time-dependent) (NN redistribution)) (PP (IN of) (NP (NP (NP (NN _PROT1_)) (, ,) (NP (NN -delta)) (CC and) (NP (NN -epsilon))) (NNS isoforms))) (PP (IN between) (NP (NP (DT the) (NP (NN membrane)) (CC and) (NP (JJ cytosolic) (NNS fractions))) (VP (VBD occurred) (PP (IN in) (NN response) (TO to) (NP (ADJP (CD 100) (NN pM)) (NN _PROT2_)))))))))
-1 #(S1 (S (NP (NP (NN Pretreatment)) (PP (IN for) (NP (CD 24) (NN h))) (PP (IN with) (NP (ADJP (CD 1) (NN microM)) (NN PMA)))) (VP (VP (VBD downregulated) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NP (NN _PROT1_)) (CC and) (NP (NN -delta))) (, ,) (CONJP (CC but) (RB not)) (NP (NN _PROT2_)) (, ,))))) (CC and) (VP (VBD prevented) (NP (NP (DT the) (JJ Ca2+-spiking) (NNS responses)) (PP (TO to) (NP (CC either) (NP (ADJP (CD 1) (NN nM)) (NN PMA)) (CC or) (NP (ADJP (CD 100) (NN pM)) (NN _PROT_)))))))))
-1 #(S1 (S (NP (NP (NN Pretreatment)) (PP (IN for) (NP (CD 24) (NN h))) (PP (IN with) (NP (ADJP (CD 1) (NN microM)) (NN PMA)))) (VP (VP (VBD downregulated) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NP (NN _PROT1_)) (CC and) (NP (NN -delta))) (, ,) (CONJP (CC but) (RB not)) (NP (NN _PROT_)) (, ,))))) (CC and) (VP (VBD prevented) (NP (NP (DT the) (JJ Ca2+-spiking) (NNS responses)) (PP (TO to) (NP (CC either) (NP (ADJP (CD 1) (NN nM)) (NN PMA)) (CC or) (NP (ADJP (CD 100) (NN pM)) (NN _PROT2_)))))))))
-1 #(S1 (S (NP (NP (NN Pretreatment)) (PP (IN for) (NP (CD 24) (NN h))) (PP (IN with) (NP (ADJP (CD 1) (NN microM)) (NN PMA)))) (VP (VP (VBD downregulated) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN -delta))) (, ,) (CONJP (CC but) (RB not)) (NP (NN _PROT1_)) (, ,))))) (CC and) (VP (VBD prevented) (NP (NP (DT the) (JJ Ca2+-spiking) (NNS responses)) (PP (TO to) (NP (CC either) (NP (ADJP (CD 1) (NN nM)) (NN PMA)) (CC or) (NP (ADJP (CD 100) (NN pM)) (NN _PROT2_)))))))))
+1 #(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NN _PROT1_) (NN activation)) (VP (VBZ is) (NP (NP (DT a) (JJ necessary) (NN step)) (PP (IN in) (NP (NP (DT the) (NN signal) (NN transduction) (NN pathway)) (VP (VBG linking) (NP (NP (JJ low) (NNS concentrations)) (PP (IN of) (NP (NN _PROT2_)))) (PP (TO to) (NP (NP (NN Ca2+) (NN spiking)) (PP (IN in) (NP (NN A7r5) (NNS cells)))))))))))))))
-1 #(S1 (S (NP (NP (NN Induction)) (PP (IN of) (NP (NP (NP (JJ fatty) (NN acid) (NN translocase/CD36)) (, ,) (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor-gamma2)) (, ,) (NP (NN _PROT1_)) (, ,) (NP (NN _PROT2_) (NNS _PROT2_) (NP (CD _PROT2_) (CC and) (CD _PROT_))) (, ,) (CC and) (NP (NN tumor) (NN necrosis) (NN factor-alpha))) (NN gene) (NN expression))) (PP (IN in) (NP (JJ human) (NN subcutaneous) (NN fat))) (PP (IN by) (NP (NN lipid) (NN infusion))))))
-1 #(S1 (S (NP (NP (NN Induction)) (PP (IN of) (NP (NP (NP (JJ fatty) (NN acid) (NN translocase/CD36)) (, ,) (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor-gamma2)) (, ,) (NP (NN _PROT1_)) (, ,) (NP (NN _PROT_) (NNS _PROT_) (NP (CD _PROT_) (CC and) (CD _PROT2_))) (, ,) (CC and) (NP (NN tumor) (NN necrosis) (NN factor-alpha))) (NN gene) (NN expression))) (PP (IN in) (NP (JJ human) (NN subcutaneous) (NN fat))) (PP (IN by) (NP (NN lipid) (NN infusion))))))
-1 #(S1 (S (NP (NP (NN Induction)) (PP (IN of) (NP (NP (NP (JJ fatty) (NN acid) (NN translocase/CD36)) (, ,) (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor-gamma2)) (, ,) (NP (NN _PROT_)) (, ,) (NP (NN _PROT1_) (NNS _PROT1_) (NP (CD _PROT1_) (CC and) (CD _PROT2_))) (, ,) (CC and) (NP (NN tumor) (NN necrosis) (NN factor-alpha))) (NN gene) (NN expression))) (PP (IN in) (NP (JJ human) (NN subcutaneous) (NN fat))) (PP (IN by) (NP (NN lipid) (NN infusion))))))
-1 #(S1 (S (S (VP (VBG Using) (NP (NP (JJ reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction)) (NN analysis)))) (, ,) (NP (NP (DT the) (NN mRNA) (NN expression)) (PP (IN of) (NP (NP (JJ fatty) (NN acid) (NN translocase) (PRN (-LRB- -LRB-) (NP (NN FAT)) (-RRB- -RRB-)) (CD /CD36)) (, ,) (NP (NN PPAR-gamma2)) (, ,) (NP (NN _PROT1_)) (, ,) (NP (NP (NN _PROT2_) (NN _PROT2_) (PRN (-LRB- _PROT2_) (NP (NN _PROT2_)) (-RRB- _PROT2_)) (CD _PROT2_)) (CC and) (NP (NN _PROT_))) (, ,) (CC and) (NP (NN tumor) (NN necrosis) (NN factor) (-LRB- -LRB-) (NN TNF) (-RRB- -RRB-) (NN -alpha))))) (VP (VBD was) (VP (VBN investigated) (PP (IN in) (NP (JJ gluteal) (JJ subcutaneous) (JJ fat) (NNS biopsies))) (PP (IN before) (CC and) (PP (IN after) (NP (NP (CD 5) (NN h) (NNS infusions)) (PP (IN of) (NP (NP (NN saline)) (CC or) (NP (NP (NP (NN Intralipid)) (PRN (-LRB- -LRB-) (NP (NP (NNP Pharmacia)) (CC and) (NP (NNP Upjohn) (, ,) (NNP Milan) (, ,) (NNP Italy))) (-RRB- -RRB-))) (CC plus) (NP (NN heparin))))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ does) (RB not) (VP (VB modify) (NP (NN insulinemia)))))))))
-1 #(S1 (S (S (VP (VBG Using) (NP (NP (JJ reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction)) (NN analysis)))) (, ,) (NP (NP (DT the) (NN mRNA) (NN expression)) (PP (IN of) (NP (NP (JJ fatty) (NN acid) (NN translocase) (PRN (-LRB- -LRB-) (NP (NN FAT)) (-RRB- -RRB-)) (CD /CD36)) (, ,) (NP (NN PPAR-gamma2)) (, ,) (NP (NN _PROT1_)) (, ,) (NP (NP (NN _PROT_) (NN _PROT_) (PRN (-LRB- _PROT_) (NP (NN _PROT_)) (-RRB- _PROT_)) (CD _PROT_)) (CC and) (NP (NN _PROT2_))) (, ,) (CC and) (NP (NN tumor) (NN necrosis) (NN factor) (-LRB- -LRB-) (NN TNF) (-RRB- -RRB-) (NN -alpha))))) (VP (VBD was) (VP (VBN investigated) (PP (IN in) (NP (JJ gluteal) (JJ subcutaneous) (JJ fat) (NNS biopsies))) (PP (IN before) (CC and) (PP (IN after) (NP (NP (CD 5) (NN h) (NNS infusions)) (PP (IN of) (NP (NP (NN saline)) (CC or) (NP (NP (NP (NN Intralipid)) (PRN (-LRB- -LRB-) (NP (NP (NNP Pharmacia)) (CC and) (NP (NNP Upjohn) (, ,) (NNP Milan) (, ,) (NNP Italy))) (-RRB- -RRB-))) (CC plus) (NP (NN heparin))))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ does) (RB not) (VP (VB modify) (NP (NN insulinemia)))))))))
-1 #(S1 (S (S (VP (VBG Using) (NP (NP (JJ reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction)) (NN analysis)))) (, ,) (NP (NP (DT the) (NN mRNA) (NN expression)) (PP (IN of) (NP (NP (JJ fatty) (NN acid) (NN translocase) (PRN (-LRB- -LRB-) (NP (NN FAT)) (-RRB- -RRB-)) (CD /CD36)) (, ,) (NP (NN PPAR-gamma2)) (, ,) (NP (NN _PROT_)) (, ,) (NP (NP (NN _PROT1_) (NN _PROT1_) (PRN (-LRB- _PROT1_) (NP (NN _PROT1_)) (-RRB- _PROT1_)) (CD _PROT1_)) (CC and) (NP (NN _PROT2_))) (, ,) (CC and) (NP (NN tumor) (NN necrosis) (NN factor) (-LRB- -LRB-) (NN TNF) (-RRB- -RRB-) (NN -alpha))))) (VP (VBD was) (VP (VBN investigated) (PP (IN in) (NP (JJ gluteal) (JJ subcutaneous) (JJ fat) (NNS biopsies))) (PP (IN before) (CC and) (PP (IN after) (NP (NP (CD 5) (NN h) (NNS infusions)) (PP (IN of) (NP (NP (NN saline)) (CC or) (NP (NP (NP (NN Intralipid)) (PRN (-LRB- -LRB-) (NP (NP (NNP Pharmacia)) (CC and) (NP (NNP Upjohn) (, ,) (NNP Milan) (, ,) (NNP Italy))) (-RRB- -RRB-))) (CC plus) (NP (NN heparin))))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ does) (RB not) (VP (VB modify) (NP (NN insulinemia)))))))))
-1 #(S1 (S (S (NP (NP (JJ Marked) (NNS increases)) (PP (IN in) (NP (NP (NP (NN FAT/CD36)) (PRN (-LRB- -LRB-) (NP (CD 724+/-18) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN PPAR-gamma2)) (PRN (-LRB- -LRB-) (NP (CD 200+/-8) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (CD 110+/-13) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (CD 120+/-7) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (CD 80+/-5) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN TNF-alpha) (NN mRNA)) (PRN (-LRB- -LRB-) (NP (CD 130+/-12) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NN pretreatment) (NNS levels)))))))) (, ,) (IN whereas) (S (NP (EX there)) (VP (VBD was) (NP (DT no) (NN change)) (PP (IN after) (NP (NN saline) (NN infusion)))))))
-1 #(S1 (S (S (NP (NP (JJ Marked) (NNS increases)) (PP (IN in) (NP (NP (NP (NN FAT/CD36)) (PRN (-LRB- -LRB-) (NP (CD 724+/-18) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN PPAR-gamma2)) (PRN (-LRB- -LRB-) (NP (CD 200+/-8) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (CD 110+/-13) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (CD 120+/-7) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (CD 80+/-5) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN TNF-alpha) (NN mRNA)) (PRN (-LRB- -LRB-) (NP (CD 130+/-12) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NN pretreatment) (NNS levels)))))))) (, ,) (IN whereas) (S (NP (EX there)) (VP (VBD was) (NP (DT no) (NN change)) (PP (IN after) (NP (NN saline) (NN infusion)))))))
-1 #(S1 (S (S (NP (NP (JJ Marked) (NNS increases)) (PP (IN in) (NP (NP (NP (NN FAT/CD36)) (PRN (-LRB- -LRB-) (NP (CD 724+/-18) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN PPAR-gamma2)) (PRN (-LRB- -LRB-) (NP (CD 200+/-8) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (CD 110+/-13) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (CD 120+/-7) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (CD 80+/-5) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN TNF-alpha) (NN mRNA)) (PRN (-LRB- -LRB-) (NP (CD 130+/-12) (NN %)) (: ;) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NN pretreatment) (NNS levels)))))))) (, ,) (IN whereas) (S (NP (EX there)) (VP (VBD was) (NP (DT no) (NN change)) (PP (IN after) (NP (NN saline) (NN infusion)))))))
-1 #(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (ADJP (FW in) (FW vivo)) (NN gene) (NN expression)) (PP (IN of) (NP (NP (NN FAT/CD36)) (, ,) (NP (NN PPAR-gamma2)) (, ,) (NP (NN _PROT1_)) (, ,) (NP (NN _PROT2_)) (, ,) (NP (NN _PROT_)) (, ,) (CC and) (NP (NN TNF-alpha)))) (PP (IN in) (NP (JJ subcutaneous) (NN adipose) (NN tissue)))) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP (NP (JJ circulating) (NNS lipids)) (ADJP (JJ independent) (PP (IN of) (NP (NN insulin)))))))))) (CC and) (SBAR (IN that) (S (NP (JJ prolonged) (NN hyperlipidemia)) (VP (MD may) (ADVP (RB therefore)) (VP (VB contribute) (PP (TO to) (NP (NP (VBN increased) (JJ fat) (NN metabolism)) (CC and) (NP (NN storage)))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT the) (VBN increased) (NN expression)) (PP (IN of) (NP (DT these) (NNS proteins)))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (ADJP (FW in) (FW vivo)) (NN gene) (NN expression)) (PP (IN of) (NP (NP (NN FAT/CD36)) (, ,) (NP (NN PPAR-gamma2)) (, ,) (NP (NN _PROT1_)) (, ,) (NP (NN _PROT_)) (, ,) (NP (NN _PROT2_)) (, ,) (CC and) (NP (NN TNF-alpha)))) (PP (IN in) (NP (JJ subcutaneous) (NN adipose) (NN tissue)))) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP (NP (JJ circulating) (NNS lipids)) (ADJP (JJ independent) (PP (IN of) (NP (NN insulin)))))))))) (CC and) (SBAR (IN that) (S (NP (JJ prolonged) (NN hyperlipidemia)) (VP (MD may) (ADVP (RB therefore)) (VP (VB contribute) (PP (TO to) (NP (NP (VBN increased) (JJ fat) (NN metabolism)) (CC and) (NP (NN storage)))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT the) (VBN increased) (NN expression)) (PP (IN of) (NP (DT these) (NNS proteins)))))))))))))))
-1 #(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (ADJP (FW in) (FW vivo)) (NN gene) (NN expression)) (PP (IN of) (NP (NP (NN FAT/CD36)) (, ,) (NP (NN PPAR-gamma2)) (, ,) (NP (NN _PROT_)) (, ,) (NP (NN _PROT1_)) (, ,) (NP (NN _PROT2_)) (, ,) (CC and) (NP (NN TNF-alpha)))) (PP (IN in) (NP (JJ subcutaneous) (NN adipose) (NN tissue)))) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP (NP (JJ circulating) (NNS lipids)) (ADJP (JJ independent) (PP (IN of) (NP (NN insulin)))))))))) (CC and) (SBAR (IN that) (S (NP (JJ prolonged) (NN hyperlipidemia)) (VP (MD may) (ADVP (RB therefore)) (VP (VB contribute) (PP (TO to) (NP (NP (VBN increased) (JJ fat) (NN metabolism)) (CC and) (NP (NN storage)))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT the) (VBN increased) (NN expression)) (PP (IN of) (NP (DT these) (NNS proteins)))))))))))))))
-1 #(S1 (S (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NN HEK-293) (NNS cells))) (PP (IN for) (NP (CD 2) (NN min))) (PP (IN with) (NP (NP (NN carbachol)) (, ,) (NP (NP (DT a) (JJ mAChR) (NN agonist)) (, ,) (NP (JJ lysophosphatidic) (NN acid)) (, ,) (CC or) (NP (NN ATP))) (, ,)))) (VP (VBN followed) (PP (IN by) (NP (NN agonist) (NN washout))))) (, ,) (ADVP (RB strongly)) (S (VP (VBN increased) (PRN (-LRB- -LRB-) (PP (IN by) (NP (JJ 2-3-fold))) (-RRB- -RRB-)) (NP (NP (NP (JJ maximal) (NN _PROT1_) (NN stimulation)) (PRN (-LRB- -LRB-) (NP (QP (VBN measured) (CD >/=40)) (NN min) (JJ later)) (-RRB- -RRB-))) (PP (IN by) (NP (NP (JJ epidermal) (NN growth) (NN factor)) (CC and) (NP (JJ platelet-derived) (NN growth) (NN factor)) (, ,) (CONJP (CC but) (RB not)) (NP (NN _PROT2_)))) (, ,) (CC and) (NP (NP (ADJP (RB largely) (VBN enhanced)) (NN _PROT_) (NN sensitivity)) (PP (TO to) (NP (DT these) (NN RTK) (NNS agonists)))))))))
-1 #(S1 (S (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NN HEK-293) (NNS cells))) (PP (IN for) (NP (CD 2) (NN min))) (PP (IN with) (NP (NP (NN carbachol)) (, ,) (NP (NP (DT a) (JJ mAChR) (NN agonist)) (, ,) (NP (JJ lysophosphatidic) (NN acid)) (, ,) (CC or) (NP (NN ATP))) (, ,)))) (VP (VBN followed) (PP (IN by) (NP (NN agonist) (NN washout))))) (, ,) (ADVP (RB strongly)) (S (VP (VBN increased) (PRN (-LRB- -LRB-) (PP (IN by) (NP (JJ 2-3-fold))) (-RRB- -RRB-)) (NP (NP (NP (JJ maximal) (NN _PROT1_) (NN stimulation)) (PRN (-LRB- -LRB-) (NP (QP (VBN measured) (CD >/=40)) (NN min) (JJ later)) (-RRB- -RRB-))) (PP (IN by) (NP (NP (JJ epidermal) (NN growth) (NN factor)) (CC and) (NP (JJ platelet-derived) (NN growth) (NN factor)) (, ,) (CONJP (CC but) (RB not)) (NP (NN _PROT_)))) (, ,) (CC and) (NP (NP (ADJP (RB largely) (VBN enhanced)) (NN _PROT2_) (NN sensitivity)) (PP (TO to) (NP (DT these) (NN RTK) (NNS agonists)))))))))
-1 #(S1 (S (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NN HEK-293) (NNS cells))) (PP (IN for) (NP (CD 2) (NN min))) (PP (IN with) (NP (NP (NN carbachol)) (, ,) (NP (NP (DT a) (JJ mAChR) (NN agonist)) (, ,) (NP (JJ lysophosphatidic) (NN acid)) (, ,) (CC or) (NP (NN ATP))) (, ,)))) (VP (VBN followed) (PP (IN by) (NP (NN agonist) (NN washout))))) (, ,) (ADVP (RB strongly)) (S (VP (VBN increased) (PRN (-LRB- -LRB-) (PP (IN by) (NP (JJ 2-3-fold))) (-RRB- -RRB-)) (NP (NP (NP (JJ maximal) (NN _PROT_) (NN stimulation)) (PRN (-LRB- -LRB-) (NP (QP (VBN measured) (CD >/=40)) (NN min) (JJ later)) (-RRB- -RRB-))) (PP (IN by) (NP (NP (JJ epidermal) (NN growth) (NN factor)) (CC and) (NP (JJ platelet-derived) (NN growth) (NN factor)) (, ,) (CONJP (CC but) (RB not)) (NP (NN _PROT1_)))) (, ,) (CC and) (NP (NP (ADJP (RB largely) (VBN enhanced)) (NN _PROT2_) (NN sensitivity)) (PP (TO to) (NP (DT these) (NN RTK) (NNS agonists)))))))))
-1 #(S1 (S (NP (NP (NP (DT The) (NN body) (NN mass) (NN index)) (PRN (-LRB- -LRB-) (NP (NN BMI)) (-RRB- -RRB-))) (, ,) (NP (NN _PROT1_)) (, ,) (NP (NP (NN plasma) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (, ,) (NP (NN serotonin)) (, ,) (NP (NP (NP (NP (NN thyroxine)) (PRN (-LRB- -LRB-) (NP (NN T4)) (-RRB- -RRB-))) (, ,) (NP (NP (NN triiodothyronine)) (PRN (-LRB- -LRB-) (NP (NN T3)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ reverse) (NN triiodothyronine)) (PRN (-LRB- -LRB-) (NP (NN rT3)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN serum))))) (VP (VBD were) (VP (VBN evaluated) (PP (IN for) (NP (DT each) (NN subject)))))))
-1 #(S1 (S (NP (NP (NP (JJ Dietary) (NNS intakes)) (PP (IN of) (NP (NP (NNS _PROT1_)) (, ,) (NP (NNS _PROT2_)) (CC and) (NP (NNS _PROT_)))) (PP (IN by) (NP (JJ Japanese) (NNS women)))) (CC and) (NP (NP (DT the) (JJ inverse) (NN correlation)) (PP (IN between) (NP (NP (NN quercetin) (NN intake)) (CC and) (NP (NN plasma) (NN LDL) (NN _PROT_) (NN concentration))))))))
-1 #(S1 (S (NP (NP (NP (JJ Dietary) (NNS intakes)) (PP (IN of) (NP (NP (NNS _PROT1_)) (, ,) (NP (NNS _PROT_)) (CC and) (NP (NNS _PROT2_)))) (PP (IN by) (NP (JJ Japanese) (NNS women)))) (CC and) (NP (NP (DT the) (JJ inverse) (NN correlation)) (PP (IN between) (NP (NP (NN quercetin) (NN intake)) (CC and) (NP (NN plasma) (NN LDL) (NN _PROT_) (NN concentration))))))))
+1 #(S1 (S (NP (NP (NP (JJ Dietary) (NNS intakes)) (PP (IN of) (NP (NP (NNS _PROT1_)) (, ,) (NP (NNS _PROT_)) (CC and) (NP (NNS _PROT_)))) (PP (IN by) (NP (JJ Japanese) (NNS women)))) (CC and) (NP (NP (DT the) (JJ inverse) (NN correlation)) (PP (IN between) (NP (NP (NN quercetin) (NN intake)) (CC and) (NP (NN plasma) (NN LDL) (NN _PROT2_) (NN concentration))))))))
-1 #(S1 (S (NP (NP (NP (JJ Dietary) (NNS intakes)) (PP (IN of) (NP (NP (NNS _PROT_)) (, ,) (NP (NNS _PROT1_)) (CC and) (NP (NNS _PROT2_)))) (PP (IN by) (NP (JJ Japanese) (NNS women)))) (CC and) (NP (NP (DT the) (JJ inverse) (NN correlation)) (PP (IN between) (NP (NP (NN quercetin) (NN intake)) (CC and) (NP (NN plasma) (NN LDL) (NN _PROT_) (NN concentration))))))))
+1 #(S1 (S (NP (NP (NP (JJ Dietary) (NNS intakes)) (PP (IN of) (NP (NP (NNS _PROT_)) (, ,) (NP (NNS _PROT1_)) (CC and) (NP (NNS _PROT_)))) (PP (IN by) (NP (JJ Japanese) (NNS women)))) (CC and) (NP (NP (DT the) (JJ inverse) (NN correlation)) (PP (IN between) (NP (NP (NN quercetin) (NN intake)) (CC and) (NP (NN plasma) (NN LDL) (NN _PROT2_) (NN concentration))))))))
+1 #(S1 (S (NP (NP (NP (JJ Dietary) (NNS intakes)) (PP (IN of) (NP (NP (NNS _PROT_)) (, ,) (NP (NNS _PROT_)) (CC and) (NP (NNS _PROT1_)))) (PP (IN by) (NP (JJ Japanese) (NNS women)))) (CC and) (NP (NP (DT the) (JJ inverse) (NN correlation)) (PP (IN between) (NP (NP (NN quercetin) (NN intake)) (CC and) (NP (NN plasma) (NN LDL) (NN _PROT2_) (NN concentration))))))))
+1 #(S1 (S (NP (NP (DT The) (JJ total) (NN intake)) (PP (IN of) (NP (NNS _PROT1_)))) (VP (VBD was) (VP (ADVP (RB inversely)) (VBN correlated) (PP (IN with) (NP (NP (NP (NP (DT the) (NN plasma) (JJ total) (NN _PROT2_) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN TC)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN r) (JJ =) (CD -0.236)) (, ,) (NP (NN P)) (: :) (NP (NN <) (CD 0.05)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN plasma) (NN LDL) (NN _PROT_) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN LDL-C)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN r) (JJ =) (CD -0.220)) (, ,) (NP (NN P)) (: :) (NP (NN <) (CD 0.05)) (-RRB- -RRB-))))) (, ,) (PP (IN after) (NP (NP (DT the) (NN adjustment)) (PP (IN for) (NP (NP (NN age)) (, ,) (NP (NN body) (NN mass) (NN index)) (CC and) (NP (JJ total) (NN energy) (NN intake))))))))))
+1 #(S1 (S (NP (NP (DT The) (JJ total) (NN intake)) (PP (IN of) (NP (NNS _PROT1_)))) (VP (VBD was) (VP (ADVP (RB inversely)) (VBN correlated) (PP (IN with) (NP (NP (NP (NP (DT the) (NN plasma) (JJ total) (NN _PROT_) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN TC)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN r) (JJ =) (CD -0.236)) (, ,) (NP (NN P)) (: :) (NP (NN <) (CD 0.05)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN plasma) (NN LDL) (NN _PROT2_) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN LDL-C)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN r) (JJ =) (CD -0.220)) (, ,) (NP (NN P)) (: :) (NP (NN <) (CD 0.05)) (-RRB- -RRB-))))) (, ,) (PP (IN after) (NP (NP (DT the) (NN adjustment)) (PP (IN for) (NP (NP (NN age)) (, ,) (NP (NN body) (NN mass) (NN index)) (CC and) (NP (JJ total) (NN energy) (NN intake))))))))))
-1 #(S1 (S (NP (NP (DT The) (JJ total) (NN intake)) (PP (IN of) (NP (NNS _PROT_)))) (VP (VBD was) (VP (ADVP (RB inversely)) (VBN correlated) (PP (IN with) (NP (NP (NP (NP (DT the) (NN plasma) (JJ total) (NN _PROT1_) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN TC)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN r) (JJ =) (CD -0.236)) (, ,) (NP (NN P)) (: :) (NP (NN <) (CD 0.05)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN plasma) (NN LDL) (NN _PROT2_) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NN LDL-C)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN r) (JJ =) (CD -0.220)) (, ,) (NP (NN P)) (: :) (NP (NN <) (CD 0.05)) (-RRB- -RRB-))))) (, ,) (PP (IN after) (NP (NP (DT the) (NN adjustment)) (PP (IN for) (NP (NP (NN age)) (, ,) (NP (NN body) (NN mass) (NN index)) (CC and) (NP (JJ total) (NN energy) (NN intake))))))))))
